PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML

A phase 1, open-label, non-randomized study enrolling pediatric and young adult patients with relapsed or refractory CD33+ leukemia with and without prior history of allogeneic hematopoietic cell transplantation, to examine the safety and feasibility of administering an autologous T cell product that has been genetically modified to express a Dimerizing Agent Regulated Immunoreceptor Complex (DARIC).

Trial Details

NCT ID
NCT05105152
Phase
PHASE1
Sponsor
Seattle Children's Hospital
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • SC-DARIC33
Locations (sample)
  • Seattle, Washington, United States|47.60621,-122.33207

Key Eligibility Criteria

  • Subject age ≤ 30 years. The first three enrolled subjects must be ≥ 18 years of age.
  • AML that expresses CD33 by flow cytometry and meets one of the below definitions:
  • For subjects who have previously received an allogeneic HCT, any evidence of AML re-emergence post HCT detectable by flow cytometry
  • First relapse of AML ≤ 6 months of initial diagnosis

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →